Basilea Pharmaceutica Presents New Research Data On Oncology Drug Candidate BAL27862 At International Cancer Conference
11/19/2009 10:27:56 AM
More...
|
Basilea Pharmaceutica's Toctino(R) Receives Marketing Authorization In Canada
11/18/2009 10:10:57 AM
More...
|
Basilea Pharmaceutica's Toctino(R) Receives Marketing Authorization In Switzerland
10/14/2009 11:13:00 AM
More...
|
New Efficacy Data On Basilea Pharmaceutica's Novel Antibiotic Against Multi-Resistant Gram-Negative Bacteria Presented At ICAAC
9/15/2009 10:56:09 AM
More...
|
Johnson & Johnson (JNJ), Basilea Pharmaceutica Respond to FDA Antibiotic Concerns
9/1/2009 7:48:45 AM
More...
|
National Institute for Clinical Excellence (NICE) Issues Positive Final Guidance Recommending The Use Of Basilea Pharmaceutica's Toctino(R)
8/26/2009 10:42:09 AM
More...
|
Basilea Pharmaceutica Reports 2009 Interim Results
8/14/2009 10:34:18 AM
More...
|
National Institute for Clinical Excellence (NICE) Issues Positive Final Appraisal Determination Recommending the Use of Basilea Pharmaceutica's Toctino
7/16/2009 10:39:07 AM
More...
|
Basilea Pharmaceutica Presents New Efficacy Data On BAL30072, Its Novel Antibiotic Against Gram-Negative Bacteria
5/18/2009 11:44:15 AM
More...
|
National Institute for Clinical Excellence (NICE) Issues Preliminary Recommendations for Basilea Pharmaceutica's Toctino(R)
4/30/2009 11:56:57 AM
More...
|
|